Recent briefings across the 30-day period ending 2026-06-25 recorded no material discrete corporate events or new regulatory disclosures for AbbVie Inc. Successive briefs dated 2026-06-09, 2026-06-17, and 2026-06-25 each noted the absence of new corporate announcements, with AbbVie's trailing twelve-month revenue through 31 March 2026 serving as the primary data anchor in each cycle [Brief - 2026-06-25]. No earnings revisions, product approvals, or litigation updates were identified across these reporting windows.
AbbVie's financials for the trailing twelve months ended 31 March 2026 show revenue of $62.82 billion, representing 12.43% growth year-over-year. Gross margin stood at 67.37% and operating margin at 24.41%, while net margin came in at 5.79%, with net income of $3.64 billion. EPS declined 45.83% year-over-year. The company held $9.39 billion in cash against total debt of $64.50 billion. The P/E ratio was recorded at 128.61 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership data reflects divergent positioning among large managers in the most recent 13F reporting period. Millennium Management added 61% to its ABBV position and Bridgewater Associates increased its holding by 114%, while Citadel reduced its position by 11% and AQR Capital Management reduced its position by 23% [SEC 13F - Millennium - Q1 2026] [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026]. These simultaneous additions and reductions across major institutional filers constitute the material ownership changes that motivated this report.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.48% and the 2-year yield at 4.17%, producing a normal yield curve with a spread of 31 basis points [FRED DGS10] [FRED DGS2]. AbbVie carries a substantial debt load of $64.50 billion, making the broader interest rate environment a relevant contextual factor for assessing its financing conditions [SEC 10-Q - ABBV - 2026-03-31].